A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Renata Belfort; Stephen A. Harrison; Kenneth Brown; Celia Darland; Joan Finch; Jean Hardies; Bogdan Balas; Amalia Gastaldelli; Fermin O. Tio; Joseph P. Pulcini; Rachele Berria; Z. Jennie; Sunil Kumar Dwivedi; Russell Havranek; Chris Fincke; Ralph A. DeFronzo; George A. Bannayan; Steven Schenker; Kenneth Cusi

doi:10.1056/nejmoa060326

Abstract

This is the authors' abstract. We don't add key points for this paper.

In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Belfort et al. (2006) studied this question.

synapsesocial.com/papers/69d56c2375589c71d767cc15 https://doi.org/10.1056/nejmoa060326

View Full Paper

Ask AI

Bookmark

Share

A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Abstract

Ask about this paper

Discussion

Cite This Study

A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading